- Home
- MAIA vs STTK Comparison
MAIA vs STTK Comparison
Compare MAIA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- STTK
- Stock Information
- Founded
- MAIA 2018
- STTK 2016
- Country
- MAIA United States
- STTK United States
- Employees
- MAIA N/A
- STTK N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- STTK Health Care
- Exchange
- MAIA Nasdaq
- STTK Nasdaq
- Market Cap
- MAIA 46.7M
- STTK 37.6M
- IPO Year
- MAIA 2022
- STTK 2020
- Fundamental
- Price
- MAIA $1.74
- STTK $1.00
- Analyst Decision
- MAIA
- STTK Hold
- Analyst Count
- MAIA 0
- STTK 4
- Target Price
- MAIA N/A
- STTK $3.00
- AVG Volume (30 Days)
- MAIA 417.6K
- STTK 112.0K
- Earning Date
- MAIA 08-08-2025
- STTK 07-31-2025
- Dividend Yield
- MAIA N/A
- STTK N/A
- EPS Growth
- MAIA N/A
- STTK N/A
- EPS
- MAIA N/A
- STTK N/A
- Revenue
- MAIA N/A
- STTK $4,606,000.00
- Revenue This Year
- MAIA N/A
- STTK N/A
- Revenue Next Year
- MAIA N/A
- STTK N/A
- P/E Ratio
- MAIA N/A
- STTK N/A
- Revenue Growth
- MAIA N/A
- STTK 69.65
- 52 Week Low
- MAIA $1.40
- STTK $0.69
- 52 Week High
- MAIA $4.24
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- MAIA 47.75
- STTK 47.54
- Support Level
- MAIA $1.66
- STTK $0.91
- Resistance Level
- MAIA $1.95
- STTK $1.14
- Average True Range (ATR)
- MAIA 0.12
- STTK 0.08
- MACD
- MAIA -0.00
- STTK -0.01
- Stochastic Oscillator
- MAIA 31.82
- STTK 28.35
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.